iridex - IRIX

IRIX

Close Chg Chg %
1.19 -0.04 -3.36%

Closed Market

1.15

-0.04 (3.36%)

Volume: 41.21K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Company Overview: iridex - IRIX

IRIX Key Data

Open

$1.20

Day Range

1.14 - 1.22

52 Week Range

0.78 - 1.75

Market Cap

$20.46M

Shares Outstanding

17.19M

Public Float

11.68M

Beta

0.54

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.30

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

76.69K

 

IRIX Performance

1 Week
 
-1.71%
 
1 Month
 
24.89%
 
3 Months
 
10.58%
 
1 Year
 
-30.30%
 
5 Years
 
-80.00%
 

IRIX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About iridex - IRIX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

IRIX At a Glance

IRIDEX Corp.
1212 Terra Bella Avenue
Mountain View, California 94043
Phone 1-650-940-4700 Revenue 48.67M
Industry Medical Specialties Net Income -8,910,000.00
Sector Health Technology Employees 93
Fiscal Year-end 12 / 2025
View SEC Filings

IRIX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.564
Price to Book Ratio 13.249
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.319
Enterprise Value to Sales 0.61
Total Debt to Enterprise Value 0.156

IRIX Efficiency

Revenue/Employee 523,322.581
Income Per Employee -95,806.452
Receivables Turnover 5.798
Total Asset Turnover 1.531

IRIX Liquidity

Current Ratio 1.423
Quick Ratio 0.77
Cash Ratio 0.144

IRIX Profitability

Gross Margin 39.386
Operating Margin -17.058
Pretax Margin -18.168
Net Margin -18.307
Return on Assets -28.032
Return on Equity -153.369
Return on Total Capital -132.196
Return on Invested Capital -117.353

IRIX Capital Structure

Total Debt to Total Equity 221.412
Total Debt to Total Capital 68.887
Total Debt to Total Assets 15.936
Long-Term Debt to Equity 86.552
Long-Term Debt to Total Capital 26.929
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Iridex - IRIX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
53.90M 56.97M 51.87M 48.67M
Sales Growth
+48.30% +5.69% -8.96% -6.17%
Cost of Goods Sold (COGS) incl D&A
31.23M 31.83M 30.39M 29.50M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
803.00K 1.38M 2.03M 1.42M
Depreciation
640.00K 1.16M 1.70M 1.09M
Amortization of Intangibles
163.00K 228.00K 333.00K 333.00K
COGS Growth
+50.13% +1.91% -4.51% -2.94%
Gross Income
22.67M 25.14M 21.47M 19.17M
Gross Income Growth
+45.85% +10.91% -14.58% -10.73%
Gross Profit Margin
+42.05% +44.13% +41.40% +39.39%
2021 2022 2023 2024 5-year trend
SG&A Expense
30.20M 32.68M 31.48M 27.47M
Research & Development
6.76M 7.01M 6.56M 5.18M
Other SG&A
23.44M 25.67M 24.92M 22.29M
SGA Growth
+36.50% +8.21% -3.67% -12.74%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (2.50M)
-
EBIT after Unusual Expense
(5.04M) (7.54M) (10.01M) (8.30M)
Non Operating Income/Expense
(149.00K) 60.00K 527.00K (540.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(5.18M) (7.48M) (9.48M) (8.84M)
Pretax Income Growth
+17.74% -44.30% -26.70% +6.73%
Pretax Margin
-9.62% -13.13% -18.28% -18.17%
Income Tax
40.00K 65.00K 90.00K 68.00K
Income Tax - Current - Domestic
20.00K 47.00K 31.00K 5.00K
Income Tax - Current - Foreign
18.00K 18.00K 58.00K 60.00K
Income Tax - Deferred - Domestic
- 2.00K 1.00K 3.00K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.22M) (7.55M) (9.57M) (8.91M)
Minority Interest Expense
- - - -
-
Net Income
(5.22M) (7.55M) (9.57M) (8.91M)
Net Income Growth
+17.44% -44.44% -26.81% +6.90%
Net Margin Growth
-9.69% -13.25% -18.45% -18.31%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.22M) (7.55M) (9.57M) (8.91M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.22M) (7.55M) (9.57M) (8.91M)
EPS (Basic)
-0.3388 -0.4735 -0.5934 -0.542
EPS (Basic) Growth
+25.90% -39.76% -25.32% +8.66%
Basic Shares Outstanding
15.42M 15.94M 16.13M 16.44M
EPS (Diluted)
-0.3388 -0.4735 -0.5934 -0.542
EPS (Diluted) Growth
+25.90% -39.76% -25.32% +8.66%
Diluted Shares Outstanding
15.42M 15.94M 16.13M 16.44M
EBITDA
(6.73M) (6.16M) (7.97M) (6.88M)
EBITDA Growth
-10.71% +8.50% -29.51% +13.76%
EBITDA Margin
-12.49% -10.81% -15.38% -14.13%

Snapshot

Average Recommendation HOLD Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.09 Median PE on CY Estimate N/A
Year Ago Earnings -0.54 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Iridex - IRIX

Date Name Shares Transaction Value
Dec 19, 2025 William M. Moore Director 251,550 Open market or private purchase of non-derivative security Non-derivative transaction at $1.01 per share 254,065.50
Dec 16, 2025 William M. Moore Director 280,674 Open market or private purchase of non-derivative security 0.00
Dec 16, 2025 Romeo R. Dizon Chief Financial Officer 92,685 Open market or private purchase of non-derivative security Non-derivative transaction at $0.97 per share 89,904.45
Dec 5, 2025 Romeo R. Dizon Chief Financial Officer 90,320 Open market or private purchase of non-derivative security Non-derivative transaction at $0.95 per share 85,804.00
Aug 21, 2025 Romeo R. Dizon Chief Financial Officer 43,745 Open market or private purchase of non-derivative security Non-derivative transaction at $1.16 per share 50,744.20

Iridex in the News